Do All Fibroids Need Surgery? A Gynae-Endoscopic Surgeon’s Honest Answer

A woman walks into my clinic holding a sonography report. One line on it has changed her week: “Intramural fibroid, 4.2 cm.” She has already read about hysterectomy. She has already asked her mother-in-law. She has already decided she is going to lose her uterus.

She almost certainly is not.

A fibroid on a scan is a finding, not a sentence. The decision to operate depends on what the fibroid is doing to you — not on the fact that it exists. This article walks through exactly how that decision gets made, so you can walk into your next consultation asking better questions.

The Short Answer: Most Fibroids Are Left Alone

Uterine fibroids (leiomyomas or myomas) are benign muscle tumours of the uterus. They are the single most common pelvic tumour in women of reproductive age, with a cumulative incidence exceeding 70% by age 50 in some ultrasound-based cohorts.

But prevalence is not the same as disease. Most fibroids sit quietly and are found incidentally on a scan done for something else. Reviews consistently put the proportion of women with fibroids who go on to need active treatment at roughly 25% — meaning three out of four women with fibroids will never need a procedure for them (Frontiers in Global Women’s Health, 2025).

In clinic, this is the sentence I use most often: we treat the woman, not the ultrasound report.

Why “Fibroid” On A Report Tells You Almost Nothing By Itself

Two women can have “a 4 cm fibroid” and need completely different plans. What separates them is location.

Gynaecologists classify fibroids using the FIGO system, numbered 0 to 8, based on how deeply the fibroid sits within the uterine wall:

This is why a woman with a 2 cm submucous fibroid may genuinely need a 20-minute hysteroscopic procedure, while a woman with an 8 cm subserous fibroid and normal periods may need nothing at all.

Size still matters for a specific reason: it changes which treatments will work. NICE notes that the effectiveness of drug treatment for heavy bleeding is limited once fibroids are substantially larger than 3 cm, and recommends specialist referral to discuss the full range of options at that point (NICE NG88).

What “Watch And Wait” Actually Means (And Why It’s Safe)

Expectant management is not neglect. It is a plan with a defined follow-up.

If your fibroid is not causing heavy bleeding, anaemia, pain, pressure symptoms, or a fertility problem, the appropriate management in most cases is periodic review — typically a clinical check and ultrasound at intervals your gynaecologist sets, plus a haemoglobin check if your periods are on the heavier side.

Two facts make this safer than most patients expect:

1. Fibroids do not grow in a straight line. In a prospective MRI study tracking 262 fibroids in premenopausal women, the median growth was about 9% in volume over six months — and 7% of fibroids actually shrank by more than 20% on their own. Different fibroids in the same uterus grew at different rates, and starting size did not predict how fast a fibroid would grow (Peddada et al., PNAS, 2008).

2. Menopause is on your side. Fibroids are hormone-dependent. Once oestrogen falls after menopause, the general tendency is for them to regress. For a woman at 47 with mild symptoms and a fibroid that is not growing, “wait it out with symptom control” can be a completely rational strategy.

The exception matters: a fibroid that grows after menopause, or any post-menopausal bleeding, needs prompt evaluation. Malignant change in a fibroid is rare, but new growth in a low-oestrogen state is a red flag that should never be watched casually.

When Surgery Genuinely Is The Right Answer

Surgery earns its place when fibroids are causing real harm or when nothing else will fix the problem. In my practice, these are the situations where I stop offering alternatives and start planning an operation:

1. Heavy menstrual bleeding with anaemia that has not responded to medical treatment. If your haemoglobin keeps dropping despite iron and drug therapy, the bleeding source needs removing.
2. Submucous fibroids (FIGO 0–2) distorting the cavity — particularly with infertility, recurrent miscarriage or failed IVF cycles. NICE recommends considering hysteroscopic removal for submucosal fibroids (NICE NG88).
3. Significant pressure symptoms — urinary frequency, incomplete bladder emptying, constipation, or a mass you can feel. Large fibroids can compress the ureters; obstructive uropathy is uncommon but real.
4. Pain that is genuinely fibroid-related — degeneration, or torsion of a pedunculated fibroid, which can present acutely.
5. Rapid growth in a post-menopausal woman, or imaging features that raise suspicion of something other than a benign fibroid.
6. A fibroid mechanically obstructing pregnancy plans — for example, a large cervical or lower-segment fibroid.

Notice what is not on that list: a specific number in centimetres, “because it might grow,” or “because you have completed your family.” Those are reasons to have a conversation, not automatic reasons to operate.

What You Should Be Offered Before Anyone Mentions Surgery

If bleeding is your main problem, there is a well-established medical ladder. Guidelines are clear that it should usually be climbed first.

Non-hormonal

• Tranexamic acid during your period — reduces menstrual blood loss and is taken only on bleeding days.
• NSAIDs (such as mefenamic acid) — help with both flow and cramps.
• Iron replacement — treating the anaemia is not optional, whatever else you choose.

Hormonal

• The 52 mg levonorgestrel intrauterine system (LNG-IUS) — recommended by NICE as a first-line option for heavy bleeding where fibroids are under 3 cm and the cavity is not distorted (NICE NG88). It is an outpatient insertion, and it can transform periods.
• Combined hormonal contraception or cyclical progestogens — useful when an IUS is unsuitable or declined.

GnRH-based therapy

• GnRH antagonist combination tablets (relugolix with add-back estradiol and norethisterone acetate) are now an established option. In the LIBERTY randomised withdrawal study, 78.4% of women on relugolix combination therapy maintained menstrual blood loss below 80 mL through week 76, compared with 15.1% on placebo — and importantly, heavy bleeding returned in most women after stopping (Al-Hendy et al., AJOG, 2023).
• GnRH agonists still have a role — often short-term, to correct anaemia and shrink a fibroid before surgery.

The honest caveat: medical therapy controls symptoms; it does not remove the fibroid. Most of these treatments are suppressive, and symptoms typically return when they stop. That is a trade-off worth making for a 46-year-old approaching menopause, and often the wrong trade-off for a 30-year-old with a cavity-distorting fibroid and infertility.

Uterus-Sparing Procedures Between Medicine And Hysterectomy

If drugs are not enough but you want to keep your uterus, the middle ground is wide.

Hysteroscopic myomectomy. For submucous fibroids, a resectoscope removes the fibroid through the cervix — no abdominal incision, day-care procedure, quick return to work. For the right fibroid, this is the single highest-value operation in fibroid care.

Laparoscopic (or robotic) myomectomy. Intramural and subserous fibroids are removed through keyhole incisions, and the uterine wall is repaired in layers. Compared with open surgery, patients typically have less blood loss, less pain and a faster recovery — provided the surgeon has the endoscopic suturing skill the procedure demands.

Uterine artery embolisation (UAE). An interventional radiologist blocks the fibroid’s blood supply through a catheter. It works, and it avoids surgery. The FEMME trial randomised women with symptomatic fibroids who wanted to avoid hysterectomy to either myomectomy or UAE. At two years, both groups improved substantially, with fibroid-related quality of life somewhat better after myomectomy (Manyonda et al., NEJM, 2020). At four years, the quality-of-life difference was no longer statistically significant, but the cumulative repeat-procedure rate was 24% after UAE versus 13% after myomectomy (Daniels et al., 4-year follow-up).

Radiofrequency ablation and focused ultrasound. Newer energy-based options that destroy fibroid tissue in situ. They are appealing, but availability, cost and — critically — long-term fertility data vary. Ask specifically what evidence exists for your fibroid type before choosing one.

The India Question: Are We Removing Too Many Uteruses?

This part is uncomfortable, and it needs saying.

India’s National Family Health Survey collects hysterectomy data directly from women. Analysis of NFHS-5 (2019–21) found that the most commonly reported reason for hysterectomy nationally was excessive menstrual bleeding or pain (52%), followed by fibroids or cysts (25%) and uterine disease (11.1%) (Kumari & Kundu, BMC Women’s Health, 2022).

Look at that chart again. The top reason is a symptom — one that responds to tranexamic acid, an LNG-IUS, hormonal therapy or a targeted hysteroscopic procedure in a large share of women. Researchers analysing NFHS data have gone on record recommending that primary care clinicians be better informed about the long-term effects of hysterectomy and that alternative therapies for fibroids and heavy bleeding be actively promoted (Singh et al., BMC Women’s Health, 2024).

None of this means hysterectomy is wrong. For the right woman — completed family, failed conservative treatment, severe symptoms, no desire to keep the uterus — it is definitive, effective and life-changing. It means the operation should be chosen, not defaulted into.

What I tell my patients: you are allowed to ask for a second opinion, and no good surgeon will be offended by it. If a hysterectomy has been advised as your first and only option for a fibroid, that is precisely when a second opinion is worth having.

Fibroids And Fertility: A Separate Conversation

Fibroids do not automatically cause infertility, and removing every fibroid does not automatically improve fertility. The evidence supports intervention most strongly when the fibroid distorts the uterine cavity — the submucous types.

If you are trying to conceive, three things should shape the plan:

• Cavity involvement. A saline infusion sonography or hysteroscopy answers this better than a routine scan.
• Timing. Myomectomy requires a healing interval before conception, and the mode of delivery may need review afterwards if the uterine cavity was breached.
• Everything else. Age, ovarian reserve, tubal status and the male partner’s parameters often matter more than a 3 cm intramural fibroid. Operating on the fibroid while ignoring these wastes precious time.

8 Questions To Ask Before You Consent To Fibroid Surgery

Take this list with you. Screenshot it if that’s easier.

1. Where exactly is my fibroid — is it submucous, intramural or subserous?
2. Which of my symptoms is this fibroid actually causing?
3. What happens if I do nothing for six months?
4. Which medical treatments have we tried, and for how long?
5. Can we do a myomectomy instead of removing the uterus?
6. Can this be done laparoscopically or hysteroscopically rather than open?
7. What are the chances the fibroids come back, and what would we do then?
8. If I want a child in the future, how does this operation affect that?

If a plan cannot survive those eight questions, it is not ready to be signed.

Frequently Asked Questions

What size fibroid needs surgery?

There is no universal cut-off. Symptoms and location drive the decision far more than a number in centimetres. That said, the 3 cm mark is clinically useful: NICE notes that drug treatment for heavy bleeding becomes less effective above roughly 3 cm and recommends specialist referral to discuss the wider range of options at that point (NICE NG88).

Can fibroids shrink or disappear without treatment?

Yes, some do. In the MRI-based Fibroid Growth Study, 7% of fibroids shrank by more than 20% in six months without any treatment (PNAS, 2008). Fibroids also generally regress after menopause as oestrogen levels fall. This is one reason a “wait and monitor” plan is reasonable for women near menopause with manageable symptoms.

Do fibroids turn into cancer?

Malignant change in a fibroid is rare. The concern is not that an ordinary fibroid becomes cancerous over time, but that a rare uterine sarcoma can be mistaken for a fibroid at the outset. That is why rapid growth, growth after menopause, unusual imaging features or post-menopausal bleeding always warrant prompt specialist assessment rather than routine observation.

Is laparoscopic myomectomy safe if I want children later?

For appropriately selected fibroids, yes — the uterine wall is repaired in layers precisely to preserve future pregnancy. Outcomes depend heavily on fibroid number, size and depth, and on the surgeon’s endoscopic suturing experience. Discuss your specific case and the recommended interval before trying to conceive.

Will my fibroids come back after myomectomy?

New fibroids can develop, because myomectomy removes the fibroids present, not the tendency to form them. Recurrence risk rises with multiple fibroids at the first surgery and with more years of remaining reproductive life. In the FEMME trial, 13% of the myomectomy group had a further fibroid procedure within four years, compared with 24% after embolisation (4-year follow-up).

I have fibroids but no symptoms. Do I need any follow-up at all?

Usually a periodic clinical review with ultrasound, plus a haemoglobin check if your periods have become heavier. The point of follow-up is to catch a change early new bleeding, new pressure symptoms, or unexpected growth not to talk you into surgery.

The Bottom Line

• Fibroids are common; needing surgery for them is not.
• Location beats size in almost every decision.
• Asymptomatic fibroids are usually monitored, not operated on.
• Bleeding usually deserves a proper trial of medical treatment first.
• When surgery is right, hysterectomy is one option among several not the default.

If you take one thing from this article: a fibroid on a scan does not mean you are losing your uterus. Ask what it is doing, ask what else can be tried, and ask whether your uterus can be preserved. Those three questions change outcomes.

Medically reviewed by Dr. Mohil Patel, MBBS, DGO, FMAS (Mumbai), Advanced Laparoscopic & Gynae-Endoscopic Surgeon, Ankur Maternity Home & Clinic, Ahmedabad. Last reviewed: 22 August 2026.

This article is for general education and does not replace individual medical advice. Fibroid management must be personalised. Please consult a qualified gynaecologist about your own diagnosis and treatment.

References

1. Bedggood et al. Evaluating treatment options for symptomatic uterine fibroids (MARIE WP1). Frontiers in Global Women’s Health, 2025.
2. ACOG. Management of Symptomatic Uterine Leiomyomas. Practice Bulletin No. 228, 2021.
3. NICE. Heavy menstrual bleeding: assessment and management (NG88).
4. Peddada SD et al. Growth of uterine leiomyomata among premenopausal black and white women. PNAS, 2008.
5. Manyonda I et al. Uterine-Artery Embolization or Myomectomy for Uterine Fibroids (FEMME). NEJM, 2020.
6. Daniels J et al. UAE or myomectomy: four-year follow-up of the FEMME randomised controlled trial. EJOG:X, 2021.
7. Al-Hendy A et al. LIBERTY randomized withdrawal study: relugolix combination therapy. AJOG, 2023.
8. Kumari P, Kundu J. Prevalence, socio-demographic determinants and self-reported reasons for hysterectomy in India (NFHS-5). BMC Women’s Health, 2022.
9. Singh SK, Chauhan K, Tripathi V. Key drivers of hysterectomy among women of reproductive age in three states in India. BMC Women’s Health, 2024.
10. Uterine Fibroids: Rapid Evidence Review. American Family Physician, October 2025.